 Home > Medical News > Latest Medical News > Announcement of annual results of Machinery Enterprise: Weigao, MicroPort, Yuyue...

Announcement of annual results of Machinery Enterprise: Weigao, MicroPort, Yuyue...

 Last Update: 2021-04-23
 Source: Internet
 Author: User

Tags

gn 12 2

concrete technology

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

2500%，

，iFinD，412，332020。

，，2020，。

，、，202047.
63，1203.
53%；26.
17，6527.
90%。

，、、。

2020138.
37，564.
29%；70.
07，3829.
56%。，。

Previously, in the 2020 annual report performance forecast disclosed by medical device companies, there have been many machinery companies with a market value of more than 100 billion yuan.
Among them, due to the substantial increase in the demand for testing reagents driven by the new crown epidemic, the net profit of the two medical device companies, Daan Gene and Oriental Bio, increased by more than 10 times.

　　Estimated 2021 market size of up to 8336 Yiyuan medical devices into the Golden Age

　　In recent years, due to policy support and rapid development of enterprise innovation, the medical device industry has been in a period of rapid development.
Earlier, some insiders said that the medical device industry is ushering in a golden decade.

　　Just recently, Xu Jinghe, deputy director of the National Medical Products Administration, also stated in a public speech that China's medical device industry has entered a "golden period" of vigorous development.

　　At this stage, there are medical equipment manufacturing enterprises more than 25,000, more than 897,000 enterprises.
In 2019, the main operating income of national medical devices reached more than 720 billion yuan, accounting for about 20% of the global medical device market.
Market data also shows that my country's medical device market is expected to reach 833.
6 billion yuan in 2021.

　　It is worth noting that in the 2020 corporate performance annual report, a number of medical device companies even stated that they will increase investment in technological innovation in the future, further promote the development of high and new technology, continue to strengthen the development of new products, improve product performance, and speed up products.
Upgrade iterations.

　　It can be said that while the arrival of the new crown epidemic has brought challenges to global medical capabilities, it has undoubtedly accelerated the development of the medical device industry and brought certain benefits to the industry.

　　For the upcoming golden decade, some people in the industry predict that the main flashpoints of the medical device industry in the future may appear in household medical devices, immunodiagnostics, and rehabilitation aids.

　　List of 2020 performance reports of some domestic medical device companies

　　No ranking

　　Some machinery companies are not listed temporarily because the annual report has not yet been announced

　　Shengxiang Bio

　　In 2020, the total operating income was 4.
767 billion yuan, an increase of 1,204.
67% over the same period last year; the net profit attributable to the owners of the parent company was 2.
616 billion yuan, an increase of 6,526.
24% over the same period last year.

　　The annual report shows that during the reporting period, the company actively responded to the outbreak of the global epidemic and built an overall solution for full-scenario new crown detection.
Its sales performance of products and services such as new crown nucleic acid detection reagents, nucleic acid detection equipment, related consumables, and inspection services has achieved major breakthroughs.

　　At the same time, the company's instrument sales and installed capacity growth further drove the company's incremental sales of all reagents.
In 2020, the company shipped 6,122 instruments in total, accelerating the market share of the entire line of products.

　　Daan Gene

　　In 2020, Daan Gene's operating income was 5.
345 billion yuan, a year-on-year increase of 38.
7%; net profit was 2.
433 billion yuan, a year-on-year increase of 2539.
66%.

　　Daan Gene is led by molecular diagnostic technology, and its business covers the research and development, production, and sales of clinical test reagents and instruments, as well as clinical test services in independent medical laboratories.

　　Affected by the novel coronavirus pneumonia epidemic, the market demand for novel coronavirus (2019-nCoV) nucleic acid detection kits, nucleic acid detection equipment, and related consumables will increase significantly in 2020, which has a positive impact on the company's performance.

　　Lepu Medical

　　During the reporting period, the company achieved operating income of RMB 805,826,800, an increase of 3.
35% over the same period last year; operating profit of RMB 2,236,644,100, an increase of 14.
04% over the same period of last year; total profit of RMB 2,294,841,600, an increase of 11.
22% over the same period of last year.

　　As one of the leaders of the entire industry chain in the cardiovascular field, Lepu’s medical device business is mainly composed of four platforms: the cardiovascular industry platform, the surgery & blood industry platform, the diagnostic reagent industry platform, and the home & smart medical equipment.
Its products include coronary artery Drug stents, balloons, pacemakers, occluders, heart valves, angiography machines, IVD equipment and diagnostic reagents, surgical equipment, artificial intelligence electrocardiogram equipment and home smart medical equipment, etc.

　　The annual report shows that in 2020, the company has achieved growth in all major indicators as a whole.
In the first three quarters, the operation grew steadily; in the fourth quarter, the centralized pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement of coronary stents organized by the state had a greater impact on the company's performance.
At the same time, the company increased its investment in innovative product research and development, which caused a loss in the fourth quarter.

　　Minimally Invasive Medicine

　　In 2020, MicroPort Medical achieved operating income of US$648.
7 million, a year-on-year decrease of 18.
2%, and a net loss of US$191.
3 million.

　　It is reported that Minimally Invasive Medical has eight business units, including cardiovascular intervention, orthopedics, heart rhythm management, aortic and peripheral intervention, neuro intervention, heart valve, surgical robot, and surgical instrument.

　　Among them, the proportion of operating income is composed of orthopedics: 31.
1%; heart rhythm management business: 27.
8%; cardiovascular intervention products: 22.
3%; aortic and peripheral vascular media: 10.
6%; nerve intervention: 5.
1%; heart valve: 2.
3%; surgery Equipment: 0.
7%

　　Although 2020 is the first time that Minimally Invasive Medical has seen negative growth in revenue and net profit in the past ten years, it has achieved growth in the three business units of heart valve, neurointervention and aortic and peripheral vascular intervention.

　　The main reasons for the decline in performance:

　　 (1) Affected by the novel coronavirus pneumonia epidemic, the number of outpatient visits and operations in medical institutions dropped sharply, resulting in a year-on-year decrease in the sales revenue of implantable devices during the reporting period;

　　(2) Affected by China's centralized procurement policy of coronary stents in the fourth quarter, the price subsidy adjustments for products sold in the channel but not implanted with reference to the implementation price of 2021;

　　(3) During the reporting period, according to the share award plan, certain employees, including an executive director, were granted incentive stocks to confirm the cost;

　　(4) There was no one-time investment income from the disposal of part of the equity of Shanghai MicroPort Electrophysiology Medical Technology Co.
, Ltd.
in the same period last year.

　　Weigao

　　In 2020, Weigao Group’s performance income was approximately RMB 1,134,5252,000 (2019: approximately RMB 10,383,885,000), an increase of 9.
3% over the previous year; profit income was RMB 2,03,137,000 (2019: approximately RMB 1,849,936) , An increase of 9.
7% over the previous year.

　　According to the annual report, Weigao Group's current main business is divided into medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products and other six major sectors.

　　among them:

　　The turnover of the clinical nursing business was approximately RMB 4,277.
5 million, an increase of 0.
3% over the previous year.
With a rich product portfolio, it has made up for the decline in demand caused by the limited clinical opening of the new crown epidemic, and continues to maintain a dominant position in the market in this field;

　　The turnover of the pharmaceutical packaging business was approximately RMB 169,3798,000, an increase of 32.
2% over the previous year, still maintaining a strong growth momentum.
Pre-filled syringes further expand their market influence in the field of biopharmaceutical packaging, fully guarantee the supply of COVID-19 vaccine syringes, and form a broad customer base;

　　The operating income of orthopedics business was approximately RMB 174,7774,000, an increase of 12.
4% from last year.
Through further consolidation of the market position in the spine field, increase in the market promotion of joint products, as well as the sinking of channels, the establishment of logistics platforms and other measures, it has better stimulated sales growth ；

　　The turnover of the intervention business was approximately RMB 161,1583,000, a decrease of 2.
7% from last year, mainly due to the decline in sales of the American company Airang due to the global epidemic.
The Group used resources to expand the sales of American Airang products in the Chinese market and made significant progress.

　　In 2020, the Weigao Group’s total R&D expenditure was approximately RMB411,404,000 (2019: approximately RMB406,363,000), accounting for 3.
63% (2019: 3.
91%) of revenue.

　　Diving Medical

　　In 2020, Yuyue Medical Company will achieve a total operating income of 6.
734 billion yuan, an increase of 45.
26% over the same period of the previous year.

　　The annual report shows that during the reporting period, the company's main products such as oxygen concentrators, electronic blood pressure monitors, blood glucose meters and test strips continued to maintain good growth.
Some core businesses have increased significantly, and the sales of various products have been comprehensively improved.
Among them, overseas sales have outstanding performance and business scale The growth has doubled.
In addition to properly completing the coordination and coordination of a large number of overseas orders, it has also established and expanded overseas sales channels, and the brand influence has been deepened, which provides the possibility for long-term business development.

　　The performance of online platforms is equally impressive, with a year-on-year growth rate of more than 30%.
Offline platforms continue to promote terminal refinement strategies to overcome the negative impact of the epidemic and achieve stable growth rates.

　　It is reported that Yuyue medical products are mainly concentrated in the fields of medical respiration and oxygen supply, home medical treatment and chronic disease management, disinfection control inside and outside the hospital , surgical and ophthalmic equipment, and traditional Chinese medicine equipment.

　　Wanfu Biological

　　In 2020, Wanfu Biotech’s operating income was 2810841254.
41 yuan, a year-on-year increase of 35.
64%; net profit reached 634170281.
68 yuan, a year-on-year increase of 63.
67.

　　The annual report shows that Wanfu Biological Company's existing immune colloidal gold technology platform, immunofluorescence technology platform, electrochemical technology platform, dry biochemical technology platform, chemiluminescence technology platform, molecular diagnostic technology platform, pathological diagnostic technology platform, and instrument technology platform There are nine platforms in total with the biological raw materials platform.

　　Relying on the above nine technology platforms, Wanfu Biotechnology has formed a rich product line in the fields of cardiovascular and cerebrovascular diseases, inflammation, tumors, infectious diseases, drug testing (drug abuse), eugenics and childbirth.

　　2020，：

　　、POCT

　　POCT

　　“”

　　2020，195078.
05 ，36.
24%；87524.
05，53.
33%。

　　，，、，、、DNA、。

　　，，2020，，。“”，。

　　，2020， 8,075.
93 ， 17.
98%， 4.
14%。

　　2500%，

　　，iFinD，412，332020。

　　，，2020，。

　　，、，202047.
63，1203.
53%；26.
17，6527.
90%。

　　，、、。

　　2020138.
37，564.
29%；70.
07，3829.
56%。，。

　　，2020，。，，、10。

　　20218336

　　，、，。，。

　　，，“”。

　　，2.
5，89.
7。20197200，20%。，20218336。

　　，2020，，，，，，。

　　，，，，。

　　，，、、。

　　2020

　　2020 47.
67，1,204.
67%；26.
16，6,526.
24%。

　　，，，。、、、。

　　，。2020 6,122 ，。

　　2020，53.
45，386.
7%；24.
33，2539.
66%。

　　，、、。

　　，2020（2019-nCoV）、，。

　　， 805682.
68， 3.
35%；223664.
41，14.
04%； 229484.
16 ，11.
22%。

　　，、&、、&，、、、、、、IVD、、。

　　，2020。；pharmnet.
com.
cn/news/yyzb/" target="_blank">，，。

　　20206.
487，18.
2%，1.
913。

　　，，、、、、、、、。

　　：31.
1%；：27.
8%；：22.
3%；：10.
6%；：5.
1%；：2.
3%；：0.
7%

　　2020，、。

　　：

　　（1），；

　　（2），2021；

　　（3），；

　　（4）。

　　2020，11345252000（：10,383,885,000），9.
3%；2030137000（：1849936000），9.
7%。

　　，、、、、6。

　　：

　　4267450000，0.
3%。，，；

　　1693798000，32.
2%，。，，；

　　1747774000，12.
4%，、，、，；

　　1611583000，2.
7%，，。。

　　2020，411,404,000（：406,363,000），3.
63%（：3.
91%）。

　　2020， 67.
34 ， 45.
26%，

　　，，、、，，，，，，、，，。

　　， 30%，，，。

　　，、、、。

　　2020，2810841254.
41，35.
64%；634170281.
68，63.
67.

　　，、、、、、、，。

　　，、、、、（）、。

　　2020，：

　　、POCT

　　POCT

　　“”

　　2020，195078.
05 ，36.
24%；87524.
05，53.
33%。

　　，，、，、、DNA、。

　　，，2020，，。“”，。

　　，2020， 8,075.
93 ， 17.
98%， 4.
14%。

　　2500%，

　　，iFinD，412，332020。

　　，，2020，。

　　，、，202047.
63，1203.
53%；26.
17，6527.
90%。

　　，、、。

　　2020138.
37，564.
29%；70.
07，3829.
56%。，。

　　，2020，。，，、10。

　　20218336

　　，、，。，。

　　，，“”。

　　，2.
5，89.
7。20197200，20%。，20218336。

　　，2020，，，，，，。

　　，，，，。

　　，，、、。

　　2020

　　2020 47.
67，1,204.
67%；26.
16，6,526.
24%。

　　，，，。、、、。

　　，。2020 6,122 ，。

　　2020，53.
45，386.
7%；24.
33，2539.
66%。

　　，、、。

　　，2020（2019-nCoV）、，。

　　， 805682.
68， 3.
35%；223664.
41，14.
04%； 229484.
16 ，11.
22%。

　　，、&、、&，、、、、、、IVD、、。

　　，2020。；pharmnet.
com.
cn/news/yyzb/" target="_blank">，，。

pharmnet.
com.
cn/news/yyzb/" target="_blank">pharmnet.
com.
cn/news/yyzb/" target="_blank">

　　20206.
487，18.
2%，1.
913。

　　，，、、、、、、、。

　　：31.
1%；：27.
8%；：22.
3%；：10.
6%；：5.
1%；：2.
3%；：0.
7%

　　2020，、。

　　：

　　(3) During the reporting period, according to the share award plan, certain employees, including an executive director, were granted incentive stocks to confirm the cost;

　　(4) There was no one-time investment income from the disposal of part of the equity of Shanghai MicroPort Electrophysiology Medical Technology Co.
, Ltd.
in the same period last year.

　　Weigao

　　among them:

　　In 2020, the Weigao Group’s total R&D expenditure was approximately RMB411,404,000 (2019: approximately RMB406,363,000), accounting for 3.
63% (2019: 3.
91%) of revenue.

　　Diving Medical

　　In 2020, Yuyue Medical Company will achieve a total operating income of 6.
734 billion yuan, an increase of 45.
26% over the same period of the previous year.

Disinfection disinfection disinfection

　　Wanfu Biological

　　In 2020, Wanfu Biotech’s operating income was 2810841254.
41 yuan, a year-on-year increase of 35.
64%; net profit reached 634170281.
68 yuan, a year-on-year increase of 63.
67.

　　In 2020, the main performance driving factors of Wanfu Biology are mainly due to the following reasons:

　　Hierarchical diagnosis and treatment, the sinking of medical resources promote the rapid growth of the POCT industry

　　The construction of the chest pain center boosts the company's sales of cardiovascular and cerebrovascular disease products

　　Strong demand for POCT products in clinical departments

　　Performance development driven by the impact of the new crown epidemic

　　Continuously introduce new product pipelines

　　Continuous deepening of market development

　　Human resources continue to strengthen

　　To this operation to help the company's business development

　　The strategic layout of the company's "ecosphere"

　　Jianfan Biological

　　In 2020, Jianfan Biological's operating income was RMB 1,950,780,500, an increase of 36.
24% year-on-year; net profit was RMB 875,240,500, an increase of 53.
33% year-on-year.

　　According to the annual report, as a blood purification product provider with innovative technology, Jianfan Bio is mainly engaged in the research and development, production and sales of hemoperfusion-related products and equipment.
Its products include disposable hemoperfusion devices and single-use plasma bilirubin adsorption Detector, DNA immunoadsorption column, hemodialysis powder and blood purification equipment, etc.

　　Regarding the performance growth, Jianfan Biological said that in 2020, the new crown epidemic will raging around the world, and Jianfan Biological has turned crises into opportunities with the significant therapeutic effects of the company's products in the field of critical illness.
The company's technology or products have been continuously written into the "new coronavirus pneumonia diagnosis and treatment plan or guide" at home and abroad, and the brand image has been improved.

　　In terms of research and development, in 2020, Jianfan Bio will invest RMB 80,759,300 in research and development, an increase of 17.
98% year-on-year, accounting for 4.
14% of the company's total operating income.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.